Maynard Um
-
-
-
-
-
-
-
Leerink Partners Starts Xilio Therapeutics Inc (XLO) at Outperform, PT $2
-
-
-
-
-
-
-
Xilio Therapeutics (XLO) Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colo
-
-
-
-
-
-
400,869 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

